Related references
Note: Only part of the references are listed.HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men
Prince A. Adu et al.
LIVER INTERNATIONAL (2021)
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously difficult to treat patients infected with hepatitis C virus genotype 1 and 4
Dorota Zarebska-Michaluk et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals A multicenter study
Soraia M. Machado et al.
MEDICINE (2020)
Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020
Waldemar Halota et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2020)
Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study
A. Piekarska et al.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2020)
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
Jose Manuel Sousa et al.
PLOS ONE (2019)
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)
Anne Boerekamps et al.
JOURNAL OF HEPATOLOGY (2019)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Juergen K. Rockstroh et al.
CLINICAL INFECTIOUS DISEASES (2018)
All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings
Juan Berenguer et al.
HEPATOLOGY (2018)
Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
J. Bischoff et al.
HIV MEDICINE (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
Treatment of hepatitis C virus genotype 4 in the DAA era
Antonio Di Biagio et al.
VIROLOGY JOURNAL (2018)
Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
Claudia Minosse et al.
INFECTION AND DRUG RESISTANCE (2018)
Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy
L. Milazzo et al.
HIV MEDICINE (2017)
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients
Jordi Navarro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
Juergen K. Rockstroh et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
David Wyles et al.
CLINICAL INFECTIOUS DISEASES (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study
Nazrul Islam et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)
Christophe Hezode et al.
ANTIVIRAL THERAPY (2016)
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
Ira Jacobson et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study
Robert Flisiak et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2016)
Prevalence and Risk Factors of HCV/HN Co-Infection and HCV Genotype Distribution in North-Eastern Poland
Anna Grzeszczuk et al.
HEPATITIS MONTHLY (2015)
Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4
Christophe Moreno et al.
JOURNAL OF HEPATOLOGY (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Juergen K. Rockstroh et al.
LANCET HIV (2015)
Hepatitis C genotype 4: The past, present, and future
Tawhida Y. Abdel-Ghaffar et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
HIV, Age, and the Severity of Hepatitis C Virus-Related Liver Disease A Cohort Study
Gregory D. Kirk et al.
ANNALS OF INTERNAL MEDICINE (2013)
Viral hepatitis and HIV co-infection
Vincent Soriano et al.
ANTIVIRAL RESEARCH (2010)
Emergence of Hepatitis C Virus Genotype 4: Phylogenetic Analysis Reveals Three Distinct Epidemiological Profiles
Joep de Bruijne et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Hepatitis C genotype 4: What we know and what we don't yet know
Sanaa M. Kamal et al.
HEPATOLOGY (2008)
Therapeutic issues in HIV/HCV-coinfected patients
M. S. Sulkowski et al.
JOURNAL OF VIRAL HEPATITIS (2007)
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1
Sandra Franco et al.
VIRUS RESEARCH (2007)
High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain):: Phylogenetic and epidemiological analyses
Nieves Fernandez-Arcas et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Share Paper
